Publications by authors named "Nakasone H"
Fludarabine and myeloablative busulfan (FluBu4) in allogeneic hematopoietic stem cell transplantation (HSCT) for older people have not been adequately examined. This retrospective study analyzed data from a large-scale, nationwide database in Japan. Adult patients (> 15 years old, y/o) who received their first HSCT with FluBu4 for hematological malignancies were included.
View Article and Find Full Text PDFWe previously reported that the area under the curve of log-transformed cytomegalovirus antigenemia (CMV-AUC) until 100 days after allogeneic hematopoietic cell transplantation (allo-HCT) was associated with an increased risk of non-relapse mortality. We applied a risk-adapted letermovir (LTV) prophylaxis strategy guided by a risk score that predicts a higher CMV-AUC. First, we retrospectively analyzed 278 allo-HCT recipients between 2007 and 2017 (Period 1).
View Article and Find Full Text PDFBackground: Patients with adult T-cell leukemia/lymphoma (ATL) are considered to have worse outcomes after allogeneic hematopoietic stem cell transplantation (allo-HSCT) than patients with other hematological malignancies, owing to high risk of relapse and immunocompromised status. However, no studies have compared transplant outcomes between patients with ATL and those with other hematological malignancies using a large-scale database.
Objectives: To compare transplant outcomes between patients with ATL and those with other leukemias and to identify factors contributing to worse transplant outcomes in ATL patients.
In unrelated allogeneic hematopoietic cell transplantation (allo-HCT), older and/or HLA-mismatched donors are known risk factors for survival outcomes. In healthy individuals, cytomegalovirus (CMV) seropositivity is associated with impaired adaptive immune systems. We assessed whether the adverse effects of donor risk factors are influenced by the donor CMV serostatus.
View Article and Find Full Text PDFBackground: A biodegradable nonwoven fabric that can be used to extract adipose-derived stem cells (ADSCs) from adipose tissue slices was developed, which were cultured rapidly without enzymatic treatment. The extracted and cultured ADSCs remain on the nonwoven fabric and form a thick cell sheet. The aim was to use the thick cell sheet as a treatment by transplanting it into the living body.
View Article and Find Full Text PDFArticle Synopsis
- The study compares outcomes of unrelated cord blood transplantation (UCBT) and haploidentical transplantation with posttransplant cyclophosphamide (PTCy-haplo) in patients without a matched donor, focusing on the impact of CD34 cell counts in cord blood.
- Data from 2014 to 2020 was analyzed, categorizing UCBT cases into those with high (≥0.84 × 10/kg) and low (<0.84 × 10/kg) CD34 cell counts, revealing better neutrophil engraftment in PTCy-haplo compared to both UCB groups.
- While UCB-H showed similar nonrelapse mortality (NRM) and overall survival
We retrospectively evaluated the impacts of using granulocyte colony-stimulating factor (G-CSF) and its timing on posttransplant outcomes for 9766 adults with acute myeloid leukemia (AML) between 2013 and 2022 using a Japanese database. We separately evaluated three distinct cohorts based on graft type: 3248 received bone marrow transplantation (BMT), 3066 received peripheral blood stem cell transplantation (PBSCT), and 3452 received single-unit cord blood transplantation (CBT). Multivariate analysis showed that G-CSF administration significantly accelerated neutrophil recovery after BMT, PBSCT, and CBT.
View Article and Find Full Text PDFArticle Synopsis
- Dysregulation of BDNF is linked to Alzheimer's disease, and this study examined its expression in the hippocampus of 5xFAD mice, focusing on sex and age.
- At 3 months, female wild-type mice had higher Bdnf mRNA levels than males, but this difference disappeared in female 5xFAD mice.
- By 6 months, female 5xFAD mice showed a significant decrease in full-length TrkB receptor mRNA while increased levels of truncated TrkB were observed in both sexes, highlighting potential disruptions in BDNF signaling due to Alzheimer's.
- The research indicates that certain Bdnf splice variants are maintained at higher levels in young female mice but may be affected by Alzheimer's
Allogeneic hematopoietic stem cell transplantation from a female donor to a male recipient (female-to-male allo-HCT) is a well-established risk factor for chronic graft-versus-host disease (GVHD) and non-relapse mortality (NRM). The inferior outcomes of female-to-male allo-HCT are considered to be due to allo-immunity against H-Y antigens. However, the influence of minor histocompatibility antigens in haplo-identical allo-HCT remains to be elucidated.
View Article and Find Full Text PDFArticle Synopsis
- HLA-haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide (PTCy-haplo) is becoming a safer and more available option compared to matched unrelated donor (MUD) transplants for acute myeloid leukemia (AML).
- * A nationwide study found that while PTCy-haplo has a slower hematopoietic recovery and higher infection-related deaths, it also shows lower rates of severe graft-versus-host disease (GVHD) compared to ATG-free MUD transplants.
- * Overall survival rates were similar across all transplant types, suggesting that PTCy-haplo could be a viable option for AML patients lacking an HLA-matched donor.
Systemic corticosteroid therapy is a well-established first-line treatment for grades II-IV acute graft-versus-host disease (aGVHD). Recently, several developments have occurred, including the introduction of transplantation from human leukocyte antigen (HLA) haploidentical donors using post-transplant cyclophosphamide (PTCY-Haplo), and improvements in prognosis after cord blood transplantation (CBT) in Japan. This study aimed to analyze the association between donor sources and outcomes in patients with aGVHD.
View Article and Find Full Text PDFArticle Synopsis
- Bendamustine (BDM) has shown effectiveness in treating certain lymphomas with minimal side effects, but its impact on ATL had not been studied.
- This research demonstrated that combining BDM with tucidinostat enhances cytotoxic effects and could potentially extend survival in patients with relapsed or refractory ATL, warranting further clinical investigation.
A prospective multicenter observational study of organ response was conducted in patients with chronic GVHD diagnosed by the NIH criteria. When response was assessed at 12 months (12 M) in 118 patients, 74.6% were classified as responders and 25.
View Article and Find Full Text PDFBackground Aims: Pre-transplant lung dysfunction is known to be a risk factor for non-relapse mortality (NRM) after allogeneic hematopoietic cell transplantation (allo-HCT). It is unclear which cell source gives better outcomes for patients with pulmonary dysfunction.
Methods: We analyzed 3289 adult patients with standard-risk disease who had received HLA-matched allo-HCT, and compared outcomes between those who received peripheral blood stem cell (PBSC) vs.
Article Synopsis
- - A study was conducted to assess whether changing antibiotics or adding glycopeptide antibiotics helps patients with persistent febrile neutropenia (FN) after autologous hematopoietic cell transplantation (auto-HCT) recover faster.
- - The analysis involved 208 patients, and it found no significant improvement in recovery time for those who switched antibiotics; in fact, adding glycopeptides was linked to a longer recovery time.
- - The conclusion suggested that routine changes in antibiotics might not be beneficial for treating persistent FN after auto-HCT, indicating a need to reconsider common antibiotic management practices in such cases.
Article Synopsis
- Ruxolitinib treatment has potential benefits for quality of life and survival in patients with primary myelofibrosis (PMF), leading to questions about the best timing for allogeneic hematopoietic cell transplantation (HCT) in this context.
- A Markov model analysis revealed that delayed HCT after ruxolitinib failure generally offers better outcomes in terms of life expectancy and quality-adjusted life years (QALYs) compared to immediate HCT.
- The study found that delayed HCT was particularly beneficial for patients aged 60 and older, while it was equivalent for those younger than 60, suggesting a more strategic approach to transplantation timing may enhance patient outcomes.
Article Synopsis
- The study investigates the effect of letermovir (LTV), an anti-CMV drug, on the incidence of HHV-6 encephalitis in patients who underwent hematopoietic stem cell transplantation (HSCT).
- Among 7985 adult patients analyzed, the incidence of HHV-6 encephalitis at day 100 post-HSCT was found to be significantly lower in the LTV group (2.8%) compared to those receiving broad-spectrum antivirals (11.5%).
- The analysis suggests that broad-spectrum antiviral prophylaxis is linked to a higher risk of HHV-6 encephalitis, indicating a need for further research to understand this unexpected association.
Hematopoietic cell transplantation (HCT) is considered a curative treatment for hematological malignancies. However, HCT recipients often face complications such as graft-versus-host disease (GVHD) and disease relapse. Clinical factors like age and HLA disparity are recognized as risks for GVHD.
View Article and Find Full Text PDFBackground: Mobilized peripheral blood stem cells (PBSC) have been widely used instead of bone marrow (BM) as the graft source for allogeneic hematopoietic cell transplantation (HCT). Although early studies demonstrated no significant differences in survival between PBSC transplantation (PBSCT) and BM transplantation (BMT) from human leukocyte antigen (HLA)-identical sibling donors to adults with hematological malignancies, recent results have been unclear.
Objective: The objective of this retrospective study was to compare overall survival (OS), relapse, non-relapse mortality (NRM), hematopoietic recovery and graft-versus-host disease (GVHD) between PBSCT and BMT according to the time period of HCT (2003-2008, 2009-2014, or 2015-2020).
Background: As the Japanese population may have less genetic diversity than other ethnic groups, treatment outcomes may be affected when allogeneic hematopoietic cell transplantation is performed in other races. However, evidence explaining the effect of racial differences is limited.
Methods: We used the Japanese National Database to examine the outcomes of first allogeneic bone marrow transplantations (BMTs) performed between Japanese and non-Japanese patients from 1996 to 2021.
Article Synopsis
- * Specific comorbidities, especially infections and moderate/severe hepatic conditions, significantly increased the risk of NRM, with renal comorbidity being highlighted as the most detrimental for OS across both donor groups.
- * The findings suggest that when selecting unrelated donors for HCT, it's crucial to consider not just the donor's match but also the patient's specific comorbid conditions, like cardiac and renal issues
Higher rate of nonrelapse mortality (NRM) remains yet to be resolved in umbilical cord blood transplantation (UCBT). Considering that UCBT has some unique features compared with allogeneic hematopoietic cell transplantation from other graft sources, a UCBT-specific NRM risk assessment system is required. Thus, in this study, we sought to develop a UCBT-specific NRM Risk Assessment (CoBRA) score.
View Article and Find Full Text PDFArticle Synopsis
- * Data from over 10,000 patients revealed no significant differences in overall survival or complications between the two methods, but PB recipients had a higher rate of chronic graft-versus-host disease (GVHD), impacting long-term survival quality.
- * Findings suggest that while both sources are viable, BM might be more beneficial for certain patients, particularly those with specific types of cancers or higher comorbidity, emphasizing the need for personalized transplant strategies.